Gisadenafil (besylate)

Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP) [1].

Product Specifications

CAS Number

[334827-98-4]

Product Name Alternative

UK 369003-26

UNSPSC

12352005

Hazard Statement

H361, H412

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/gisadenafil-besylate.html

Purity

99.60

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C2=NN(CCOC)C(CC)=C2N=C(C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CN=C3OCC)N1.O=S(C5=CC=CC=C5)(O)=O

Molecular Formula

C29H39N7O8S2

Molecular Weight

677.79

Precautions

H361, H412

References & Citations

[1]Silva J, et al. Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. J Neuroinflammation. 2012 Nov 20;9:253.|[2]Rawson DJ, et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem. 2012 Jan 1;20 (1) :498-509.